Tildrakizumab

Tildrakizumab is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light). Tildrakizumab is a type of drug called a monoclonal antibody, which works by blocking a certain protein in the body that can cause inflammation.

Tildrakizumab is a medication used to treat moderate-to-severe plaque psoriasis in adults. Here's a breakdown of its key aspects:

Brand Names:

• Ilumya
• Ilumetri

Type of Drug:

• Monoclonal antibody: It's a man-made protein designed to target specific components of the immune system.

How it Works:

• Tildrakizumab targets a protein called interleukin-23 (IL-23), which plays a role in inflammation associated with psoriasis. By blocking IL-23, tildrakizumab helps reduce inflammation and improve symptoms of psoriasis.

Conditions Treated:

• Adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Dosage:

• Tildrakizumab is given as a subcutaneous injection (under the skin) by a healthcare professional.
• The typical dosage is 100mg at Weeks 0, 4, and then every 12 weeks thereafter.

Important Points:

• Tildrakizumab weakens the immune system, so it may increase the risk of infections.
• It's not recommended for people with certain infections or a weakened immune system.
• Tell your doctor about all your medical conditions and medications before taking tildrakizumab.